Nutritional factors in the prevention and management of coronary artery disease and heart failure

Nutrition

Volumn 31, Issue 2, 2015, Pages 283-291

  Das, Undurti N ^a,b  

^a UND Life Sciences   (United States)

^b GAYATRI VIDYA PARISHAD COLLEGE OF ENGINEERING   (India)

Author keywords

Arrhythmias; Asymmetrical dimethylarginine; Atherosclerosis; Coronary artery disease; Cytokines; Eicosanoids; Heart failure; L arginine; Lipoxins; Magnesium; Nitric oxide; Nutrients; Polyunsaturated fatty acids; Protectins; Pyridoxine; Resolvins; Vitamins

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ARGININE; ASCORBIC ACID; C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; G PROTEIN COUPLED RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; ISOSORBIDE DINITRATE; MAGNESIUM; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PENTRAXIN 3; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN E1; PYRIDOXINE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CD59 ANTIGEN; ESSENTIAL FATTY ACID; LIPOXIN; N,N-DIMETHYLARGININE; PROSTACYCLIN; PROSTAGLANDIN I3; SERUM ALBUMIN; UNSATURATED FATTY ACID;

ACUTE HEART INFARCTION; ALBUMIN BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BINDING SITE; BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; CYTOKINE PRODUCTION; DENDRITIC CELL; DIET SUPPLEMENTATION; DISEASE FREE SURVIVAL; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FOOD INTAKE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LERICHE SYNDROME; MORTALITY; NUTRITIONAL ASSESSMENT; NUTRITIONAL REQUIREMENT; NUTRITIONAL STATUS; PREVENTIVE MEDICINE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; THROMBOCYTE ACTIVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; VASODILATATION;

ALPROSTADIL; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD59; ARGININE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; EPOPROSTENOL; FATTY ACIDS, ESSENTIAL; FATTY ACIDS, UNSATURATED; FEMALE; FOLIC ACID; HEART FAILURE; HUMANS; HYPERTENSION; LIPOXINS; MAGNESIUM; MALE; MIDDLE AGED; NITRIC OXIDE; NUTRITIONAL STATUS; SERUM ALBUMIN; VASODILATION; VITAMIN B 12; VITAMIN B 6;

EID: 84920918203     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.08.011     Document Type: Review

References (147)

1. Badawi A., Klip A., Haddad P., Cole D.E., Bailo B.G., El-Sohemy A., et al. Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes 2010, 3:173-186.
2. Das U.N. Nutritional deficiencies and the prevalence of syndrome X in South Asians. Nutrition 2002, 18:282.
3. Das U.N. Metabolic syndrome X is common in South Asians, but why and how?. Nutrition 2002, 18:774-776.
4. Huang J.H., Lu Y.F., Cheng F.C., Lee J.N., Tsai L.C. Correlation of magnesium intake with metabolic parameters, depression and physical activity in elderly type 2 diabetes patients: a cross-sectional study. Nutr J 2012, 11:41.
5. Abeywardena M.Y., Patten G.S. Role of ω3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors. Endocr Metab Immune Disord Drug Targets 2011, 11:232-246.
6. Sales C.H., Pedrosa L.F., Lima J.G., Lemos T.M., Colli C. Influence of magnesium status and magnesium intake on the blood glucose control in patients with type 2 diabetes. Clin Nutr 2011, 30:359-364.
7. Das U.N. Pathobiology of metabolic syndrome X in obese and non-obese South Asian Indians: Further discussion and some suggestions. Nutrition 2003, 19:560-562.
8. Das U.N. Pre(peri)-natal w-3 PUFA deficiency-induced hypertension and its broader implications. Hypertension Res 2012, 35:375-379.
9. Das U.N. Minerals, trace elements and vitamins interact with essential fatty acids and prostaglandins to prevent hypertension, thrombosis, hypercholesterolemia and atherosclerosis and their attendant complications. IRCS J Med Sci 1985, 13:684-686.
10. Das U.N. Hypertension and ascorbic acid. Lancet 2000, 355:1273.
11. Mahalle N.P., Garg M.K., Kulkarni M.V., Naik S.S. Differences in traditional and non-traditional risk factors with special reference to nutritional factors in patients with coronary artery disease with or without diabetes mellitus. Indian J Endocrinol Metab 2013, 17:844-850.
12. Shargorodsky M., Boaz M., Pasternak S., Hanah R., Matas Z., Fux A., et al. Serum homocysteine, folate, vitamin B12 levels and arterial stiffness in diabetic patients: which of them is really important in atherogenesis?. Diabetes Metab Res Rev 2009, 25:70-75.
13. Das U.N. Interaction(s) between nutrients, essential fatty acids, eicosanoids, free radicals, nitric oxide, antioxidants and endothelium and their relationship to human essential hypertension. Med Sci Res 2000, 28:75-83.
14. Edington J., Boorman J., Durrant E.R., Perkins A., Giffin C.V., James R., et al. Prevalence of malnutrition on admission-four hospitals in England. The Malnutrition Prevalence Group. Clin Nutr 2000, 19:191-195.
15. Bruun L.I., Bosaeus I., Bergstad I., Nygaard K. Prevalence of malnutrition in surgical patients: Evaluation of nutritional support and documentation. Clin Nutr 1999, 18:141-147.
16. Constans T., Bacq Y., Bréchot J.F., Guilmot J.L., Choutet P., Lamisse F. Protein-energy malnutrition in elderly medical patients. J Am Geriatr Soc 1992, 40:263-268.
17. Sullivan D.H., Sun S., Walls R.C. Protein-energy undernutrition among elderly hospitalized patients: a prospective study. JAMA 1999, 281:2013-2019.
18. Sullivan D.H., Walls R.C. Impact of nutritional status on morbidity in a population of geriatric rehabilitation patients. J Am Geriatr Soc 1994, 42:471-477.
19. Sullivan D.H. The utility of an admission assessment-predict in-hospital nutrient intake. J Am Geriatr Soc 1994, 42:478-480.
20. Giner M., Laviano A., Meguid M.M., Gleason J.R. In 1995 a correlation between malnutrition and poor outcome in critically ill patients still exists. Nutrition 1996, 12:23-29.
21. Bidlack W.R. Interrelationships of food, nutrition, diet and health: the National Association of State Universities and Land Grant Colleges White Paper. J Am Coll Nutr 1996, 15:422-433.
22. He J., Gu D., Wu X., Reynolds K., Duan X., Yao C., et al. Major causes of death among men and women in China. N Engl J Med 2005, 353:1124-1134.
23. Wong S., Derry F., Jamous A., Hirani S.P., Forbes A. Is undernutrition risk associated with an adverse clinical outcome in spinal cord-injured patients admitted-a spinal centre?. Eur J Clin Nutr 2014, 68:125-130.
24. Ordoñez A.M., Madalozzo Schieferdecker M.E., Cestonaro T., Cardoso Neto J., Ligocki Campos A.C. Nutritional status influences the length of stay and clinical outcomes in patients hospitalized in internal medicine wards. Nutr Hosp 2013, 28:1313-1320.
25. Gentile S., Lacroix O., Durand A.C., Cretel E., Alazia M., Sambuc R., et al. Malnutrition: a highly predictive risk factor of short-term mortality in elderly presenting-the emergency department. J Nutr Health Aging 2013, 17:290-294.
26. Paccagnella A., Morello M., Da Mosto M.C., Baruffi C., Marcon M.L., Gava A., et al. Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy. Support Care Cancer 2010, 18:837-845.
27. August D.A., Huhmann M.B. A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN 2009, 33:472-500.
28. Nassar M.F., El-Batrawy S.R., Nagy N.M. CD95 expression in white blood cells of malnourished infants during hospitalization and catch-up growth. East Mediterr Health J 2009, 15:574-583.
29. Ivers L.C., Cullen K.A., Freedberg K.A., Block S., Coates J., Webb P. HIV/AIDS, undernutrition, and food insecurity. Clin Infect Dis 2009, 49:1096-1102.
30. Aziz E.F., Javed F., Pratap B., Musat D., Nader A., Pulimi S., et al. Malnutrition as assessed by nutritional risk index is associated with worse outcome in patients admitted with acute decompensated heart failure: an ACAP-HF data analysis. Heart Int 2011, 6:E2.
31. Larsson J., Andersson M., Askelöf N., Bark T. Malnutrition common in Swedish hospitals. Risk of complications and prolonged care increases. Nord Med 1994, 109:292-295.
32. Reilly J.J., Hull S.F., Albert N., Waller A., Bringardener S. Economic impact of malnutrition: A model system for hospitalized patients. JPEN 1988, 12:371-376.
33. Chima C.S., Barco K., Dewitt M.L., Maeda M., Teran J.C., Mullen K.D. Relationship of nutritional status-length of stay, hospital costs, and discharge status of patients hospitalized in the medicine service. J Am Diet Assoc 1997, 97:975-978.
34. Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. N Engl J Med 1991, 325:525-532.
35. Buzby G.P., Knox L.S., Crosby L.O., Eisenberg J.M., Haakenson C.M., McNeal G.E., et al. Study protocol: a randomized clinical trial of total parenteral nutrition in malnourished surgical patients. Am J Clin Nutr 1988, 47:366-381.
36. Bouillanne O., Morineau G., Dupont C., Coulombel I., Vincent J.P., Nicolis I., et al. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 2005, 82:777-783.
37. Mijan-de-la-Torre A. Recent insights on chronic heart failure, cachexia and nutrition. Curr Opin Clin Nutr Metab Care 2009, 12:251-257.
38. Schiffman S.S. Taste and smell in disease (first of two parts). N Engl J Med 1983, 308:1275-1279.
39. Jacobsson A., Pihl E., Mårtensson J., Fridlund B. Emotions, the meaning of food and heart failure: a grounded theory study. J Adv Nurs 2004, 46:514-522.
40. Anker S.D., Sharma R. The syndrome of cardiac cachexia. Int J Cardiol 2002, 85:51-66.
41. Paccagnella A., Calò M.A., Caenaro G., Salandin V., Jus P., Simini G., et al. Cardiac cachexia: Preoperative and postoperative nutrition management. JPEN 1994, 18:409-416.
42. Fonarow G.C., Stevenson L.W., Walden J.A., Livingston N.A., Steimle A.E., Hamilton M.A., et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997, 30:725-732.
43. Kinugasa Y., Kato M., Sugihara S., Hirai M., Yamada K., Yanagihara K., et al. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 2013, 77:705-711.
44. Hara M., Sakata Y., Nakatani D., Suna S., Usami M., Matsumoto S., et al. Low levels of serum n-3 polyunsaturated fatty acids are associated with worse heart failure-free survival in patients after acute myocardial infarction. Circ J 2013, 77:153-162. for the Osaka Acute Coronary Insufficiency Study (OACIS) Investigators.
45. Das U.N. Clinical laboratory tools to diagnose inflammation. Adv Clin Chem 2006, 41:189-229.
46. Hudzik B., Szkodzinski J., Romanowski W., Danikiewicz A., Wilczek K., Lekston A., et al. Serum interleukin-6 concentration reflects the extent of asymptomatic left ventricular dysfunction and predicts progression-heart failure in patients with stable coronary artery disease. Cytokine 2011, 54:266-271.
47. Kosmala W., Derzhko R., Przewlocka-Kosmala M., Orda A., Mazurek W. Plasma levels of TNF-alpha, IL-6, and IL-10 and their relationship with left ventricular diastolic function in patients with stable angina pectoris and preserved left ventricular systolic performance. Coron Artery Dis 2008, 19:375-382.
48. Petretta M., Condorelli G.L., Spinelli L., Scopacasa F., de Caterina M., Leosco D., et al. Circulating levels of cytokines and their site of production in patients with mild-severe chronic heart failure. Am Heart J 2000, 140:E28.
49. Kempf T., Wollert K.C. Growth-differentiation factor-15 in heart failure. Heart Fail Clin 2009, 5:537-547.
50. Wollert K.C., Kempf T. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 2012, 9:337-345.
51. Kuwahara M., Yamashita M., Shinoda K., Tofukuji S., Onodera A., Shinnakasu R., et al. The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-β and suppresses T(H)2 differentiation. Nat Immunol 2012, 13:778-786.
52. Vaday G.G., Schor H., Rahat M.A., Lahat N., Lider O. Transforming growth factor-beta suppresses tumor necrosis factor alpha-induced matrix metalloproteinase-9 expression in monocytes. J Leukoc Biol 2001, 69:613-621.
53. Kitamura M., Sütö T., Yokoo T., Shimizu F., Fine L.G. Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol 1996, 156:2964-2971.
54. Link J., He B., Navikas V., Palasik W., Fredrikson S., Söderström M., et al. Transforming growth factor-beta 1 suppresses autoantigen-induced expression of pro-inflammatory cytokines but not of interleukin-10 in multiple sclerosis and myasthenia gravis. J Neuroimmunol 1995, 58:21-35.
55. Das U.N. Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus and coronary heart disease. Prostaglandins Leukot Essent Fatty Acids 1995, 52:387-391.
56. Das U.N. Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease?. Lipids Health Dis 2008, 7:19.
57. Mozaffarian D., Lemaitre R.N., King I.B., Song X., Huang H., Sacks F.M., et al. Plasma phospholipid long-chain ω-3 fatty acids and total and cause-specific mortality in older adults: A cohort study. Ann Intern Med 2013, 158:515-525.
58. Mozaffarian D., Lemaitre R.N., King I.B., Song X., Spiegelman D., Sacks F.M., et al. Circulating long-chain ω-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med 2011, 155:160-170.
59. Lu Y., Vaarhorst A., Merry A.H., Dollé M.E., Hovenier R., Imholz S., et al. Markers of endogenous desaturase activity and risk of coronary heart disease in the CAREMA cohort study. PLoS One 2012, 7:E41681.
60. Masson S., Marchioli R., Mozaffarian D., Bernasconi R., Milani V., Dragani L., et al. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. Am Heart J 2013, 165:208-215.
61. Breviario F., d'Aniello E.M., Golay J., Peri G., Bottazzi B., Bairoch A., et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related-C-reactive protein and serum amyloid P component. J Biol Chem 1992, 267:22190-22197.
62. Garlanda C., Bottazzi B., Bastone A., Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005, 23:337-366.
63. Nauta A.J., Bottazzi B., Mantovani A., Salvatori G., Kishore U., Schwaeble W.J., et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1 q. Eur J Immunol 2003, 33:465-473.
64. Latini R., Maggioni A.P., Peri G., Gonzini L., Lucci D., Mocarelli P., et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
65. Kazemian P., Kazemi-Bajestani S.M., Alherbish A., Steed J., Oudit G.Y. The use of ω-3 poly-unsaturated fatty acids in heart failure: a preferential role in patients with diabetes. Cardiovasc Drugs Ther 2012, 26:311-320.
66. Sakabe M., Shiroshita-Takeshita A., Maguy A., Dumesnil C., Nigam A., Leung T.K., et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 2007, 116:2101-2109.
67. Serebruany V.L., Miller M., Pokov A.N., Lynch D., Jensen J.K., Hallén J., et al. Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriacylglycerolmia. Cardiology 2011, 118:187-194.
68. Das U.N. Prostaglandins and cardiac arrhythmias. Med J Aust 1981, 2:157-158.
69. Das U.N. Prostacyclin as an endogenous antiarrhythmic agent. Basic Res Cardiol 1983, 78:716-718.
70. Das U.N. Lipoxin A4 may function as an endogenous antiarrhythmic molecule. Med Hypotheses 2011, 76:14-16.
71. Das U.N. Polyunsaturated fatty acids in heart failure. Circ J 2013, 77:1915-1916.
72. Das U.N. Long-chain polyunsaturated fatty acids, endothelial lipase, and atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 2005, 72:173-179.
73. 5 desaturases may be a factor in the initiation and progression of atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 2007, 76:251-268.
74. Das U.N. Do polyunsaturated fatty acids behave as endogenous "polypill"?. Med Hypotheses 2008, 70:430-434.
75. Das U.N. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, antiarrhythmic, antihypertensive, antiatherosclerotic, antiinflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis 2008, 7:37.
76. Das U.N. Lipoxins, resolvins, protectins, maresins and nitrolipids: connecting lipids, inflammation, and cardiovascular disease risk. Curr Cardiovasc Risk Rep 2010, 4:24-31.
77. Das U.N. A defect in δ6 and δ5 desaturases may be a factor in the initiation and progression of insulin resistance, the metabolic syndrome and ischemic heart disease in South Asians. Lipid Health Dis 2010, 9:130.
78. Awan N.A., Needham K.E., Evenson M.K., Hermanovich J., Gradman M., Mason D.T. Beneficial effects of prostaglandin E1 on myocardial energetics and pump performance in severe CHF. Acta Med Scand Suppl 1981, 652:169-172.
79. Miller R.R., Vismara L.A., Zelis R., Amsterdam E.A., Mason D.T. Clinical use of sodium nitroprusside in chronic ischemic heart disease. Effects on peripheral vascular resistance and venous tone and on ventricular volume, pump and mechanical performance. Circulation 1975, 51:328-336.
80. Das U.N. Molecular basis of health and disease 2011, Springer, New York.
81. Wang W., Diamond S.L. Does elevated nitric oxide production enhance the release of prostacyclin from shear stressed aortic endothelial cells?. Biochem Biophys Res Commun 1997, 233:748-751.
82. Faletti A., Pérez Martínez S., Perotti C., de Gimeno M.A. Activity of ovarian nitric oxide synthase (NOs) during ovulatory process in the rat: relationship with prostaglandins (PGs) production. Nitric Oxide 1999, 3:340-347.
83. Wen F., Watanabe K., Yoshida M. Nitric oxide enhances PGI(2)production by human pulmonary artery smooth muscle cells. Prostaglandins Leukot Essent Fatty Acids 2000, 62:369-378.
84. Sakai M., Minami T., Hara N., Nishihara I., Kitade H., Kamiyama Y., et al. Stimulation of nitric oxide release from rat spinal cord by prostaglandin E2. Br J Pharmacol 1998, 123:890-894.
85. Das U.N. Can free radicals induce coronary vasospasm and acute myocardial infarction?. Med Hypotheses 1992, 39:90-94.
86. Serhan C.N., Hamberg M., Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci U S A 1984, 81:5335-5339.
87. Moncada S., Higgs E.A., Vane J.R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1977, 1:18-20.
88. Wang X., Lin H., Gu Y. Multiple roles of dihomo-γ-linolenic acid against proliferation diseases. Lipids Health Dis 2012, 11:25.
89. Serhan C.N., Arita M., Hong S., Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-Derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004, 39:1125-1132.
90. Mayer K., Schmidt R., Muhly-Reinholz M., Bögeholz T., Gokorsch S., Grimminger F., et al. Invitro mimicry of essential fatty acid deficiency in human endothelial cells by TNFα impact of ω-3 versus ω-6 fatty acids. J Lipid Res 2002, 43:944-951.
91. Das U.N. Metabolic syndrome pathophysiology: the role of essential fatty acids and their metabolites 2010, Wiley-Blackwell Publishers, Ames, IA.
92. Dückelmann C., Mittermayer F., Haider D.G., Altenberger J., Eichinger J., Wolzt M. Asymmetrical dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 2007, 27:2037-2042.
93. Annuk M., Zilmer M., Fellström B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: impact on cardiovascular disease. Kidney Int Suppl 2003, 84:S50-S53.
94. Hermansen S.E., Kalstad T., How O.J., Myrmel T. Inflammation and reduced endothelial function in the course of severe acute heart failure. Transl Res 2011, 157:117-127.
95. Tutarel O., Denecke A., Bode-Böger S.M., Martens-Lobenhoffer J., Lovric S., Bauersachs J., et al. Asymmetrical dimethylarginine-more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease. PLoS One 2012, 7:E33795.
96. El-Mesallamy H.O., Abdel Hamid S.G., Gad M.Z. Oxidative stress and asymmetrical dimethylarginine are associated with cardiovascular complications in hemodialysis patients: Improvements by l-arginine intake. Kidney Blood Press Res 2008, 31:189-195.
97. Das U.N., Repossi G., Dain A., Eynard A.R. -arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes. Front Biosci 2011, 16:13-20.
98. Böger G.I., Rudolph T.K., Maas R., Schwedhelm E., Dumbadze E., Bierend A., et al. Asymmetrical dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: effect of combination with oral l-arginine. J Am Coll Cardiol 2007, 49:2274-2282.
99. Nishiyama Y., Ueda M., Otsuka T., Katsura K., Abe A., Nagayama H., et al. Statin treatment decreased serum asymmetrical dimethylarginine (ADMA) levels in ischemic stroke patients. J Atheroscler Thromb 2011, 18:131-137.
100. Hagiwara H., Nishiyama Y., Katayama Y. Effects of eicosapentaenoic acid on asymmetrical dimethylarginine in patients in the chronic phase of cerebral infarction: a preliminary study. J Stroke Cerebrovasc Dis 2011, 20:474-478.
101. Levine L. Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells. Lipids Health Dis 2003, 2:1.
102. Das U.N. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essent Fatty Acids 2001, 65:37-40.
103. Notarnicola M., Messa C., Refolo M.G., Tutino V., Miccolis A., Caruso M.G. Synergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells. Lipids Health Dis 2010, 9:135.
104. Agheli N., Jacotot B. Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients. Br J Clin Pharmacol 1991, 32:423-428.
105. Birnbaum Y., Ye Y., Lin Y., Freeberg S.Y., Nishi S.P., Martinez J.D., et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006, 114:929-935.
106. Levy B.D. Myocardial 15-epi-lipoxin A4 generation provides a new mechanism for the immunomodulatory effects of statins and thiazolidinediones. Circulation 2006, 114:873-875.
107. Planagumà A., Pfeffer M.A., Rubin G., Croze R., Uddin M., Serhan C.N., et al. Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunol 2010, 3:270-279.
108. Spite M., Serhan C.N. Novel lipid mediators promote resolution of acute inflammation: Impact of aspirin and statins. Circ Res 2010, 107:1170-1184.
109. Lewington S., Whitlock G., Clarke R., Sherliker P., Emberson J., Halsey J., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
110. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease-quick reference guide. Available at: Accessed September 16,2014. http://www.nice.org.uk/guidance/cg67.
111. Taylor F., Huffman M.D., Macedo A.F., Moore T.H., Burke M., Davey Smith G., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013, CD004816.
112. Taylor F., Ward K., Moore T.H., Burke M., Davey Smith G., Casas J.P., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011, CD004816.
113. Das U.N. Albumin infusion therapy in stroke, sepsis and the critically ill. Current Nutr Food Sci 2008, 4:217-226.
114. Das U.N. Albumin and lipid enriched albumin for the critically ill. J Assoc Physicians India 2009, 57:53-57.
115. Iglesias J., Abernethy V.E., Wang Z., Lieberthal W., Koh J.S., Levine J.S. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am J Physiol 1999, 277(5 Pt 2):F711-F722.
116. Dobrian A., Mora R., Simionescu M., Simionescu N. Invitro formation of oxidatively-modified and reassembled human low-density lipoproteins: antioxidant effect of albumin. Biochim Biophys Acta 1993, 1169:12-24.
117. Beck R., Bertolino S., Abbot S.E., Aaronson P.I., Smirnov S.V. Modulation of arachidonic acid release and membrane fluidity by albumin in vascular smooth muscle and endothelial cells. Circ Res 1998, 83:923-931.
118. Schnitzer J.E. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol 1992, 262(1 Pt 2):H246-H254.
119. Belayev L., Marcheselli V.L., Khoutorova L., Rodriguez de Turco E.B., Busto R., Ginsberg M.D., et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 2005, 36:118-123.
120. Belayev L., Liu Y., Zhao W., Busto R., Ginsberg M.D. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001, 32:553-560.
121. Rodriguez de Turco E.B., Belayev L., Liu Y., Busto R., Parkins N., Bazan N.G., et al. Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotective therapy with human albumin. J Neurochem 2002, 83:515-524.
122. Bazan N.G. Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system. Nutrition and the brain 1990, Raven Press, New York. R.J. Wurtman, J.J. Wurtman (Eds.).
123. Das U.N. Albumin to globulin ratio and/or plasma albumin in predicting long-term mortality. Am J Surg 2014, 208:157-158.
124. Altura B.T., Altura B.M. Interactions of Mg and K on cerebral vessels-aspects in view of stroke. Review of present status and new findings. Magnesium 1984, 3:195-211.
125. Altura B.M., Altura B.T. Interactions of Mg and K on blood vessels-aspects in view of hypertension. Review of present status and new findings. Magnesium 1984, 3:175-194.
126. Altura B.M., Altura B.T., Carella A. Magnesium deficiency-induced spasms of umbilical vessels: relation to preeclampsia, hypertension, growth retardation. Science 1983, 221:376-378.
127. Turlapaty P.D., Altura B.M. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 1980, 208:198-200.
128. Joosten M.M., Gansevoort R.T., Mukamal K.J., van der Harst P., Geleijnse J.M., Feskens E.J., et al. Urinary and plasma magnesium and risk of ischemic heart disease. Am J Clin Nutr 2013, 97:1299-1306. PREVEND Study Group.
129. Siegel G., Walter A., Gustavsson H., Lindman B. Magnesium and membrane function in vascular smooth muscle. Artery 1981, 9:232-252.
130. Shechter M., Merz C.N., Rude R.K., Paul Labrador M.J., Meisel S.R., Shah P.K., et al. Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. Am Heart J 2000, 140:212-218.
131. Cook H.W., Spence M.W. Formation of monoenoic fatty acids by desaturation in rat brain homogenate. Some properties of the enzyme system of 10-day-old brain. J Biol Chem 1973, 248:1786-1793.
132. Mahfouz M.M., Kummerow F.A. Effect of magnesium deficiency on delta 6 desaturase activity and fatty acid composition of rat liver microsomes. Lipids 1989, 24:727-732.
133. Kjeldby I.K., Fosnes G.S., Ligaarden S.C., Farup P.G. Vitamin B6 deficiency and diseases in elderly people-a study in nursing homes. BMC Geriatr 2013, 13:13.
134. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1042-1050.
135. Quere I., Perneger T.V., Zittoun J., Bellet H., Gris J.-C., Daures J.-P., et al. Red blood cell methylfolic acid and plasma homocysteine as risk factors for venous thromboembolism: amatched case-control study. Lancet 2002, 359:747-752.
136. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease:probable benefits of increasing folic acid intakes. JAMA 1995, 274:1049-1057.
137. Holven K.B., Aukrust P., Holm T., Ose L., Nenseter M.S. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol 2002, 22:699-703.
138. 6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001, 103:2788-2791.
139. Das U.N. Pyridoxine, thrombosis and prostaglandins. Lancet 1981, 2:638.
140. Das U.N. Hemostatic vitamins and prostaglandins. Med J Australia 1982, 2:316.
141. Zhao M., Chen Y.-H., Dong X.-T., Zhou J., Chen X., Wang H., et al. Folic acid protects against lipopolysaccharide-induced preterm delivery and intrauterine growth restriction through its antiinflammatory effect in mice. PLoS One 2013, 8:E82713.
142. Manku M.S., Oka M., Horrobin D.F. Differential regulation of the formation of prostaglandins and related substances from arachidonic acid and from dihomo-gamma-linolenic acid. II. Effects of vitamin C. Prostaglandins Med 1979, 3:129-137.
143. Srivastava K.C. Ascorbic acid enhances the formation of prostaglandin E1 in washed human platelets and prostacyclin in rat aortic rings. Prostaglandins Leukot Med 1985, 18:227-233.
144. Horrobin D.F., Oka M., Manku M.S. The regulation of prostaglandin E1 formation: a candidate for one of the fundamental mechanisms involved in the actions of vitamin C. Med Hypotheses 1979, 5:849-858.
145. Hennig B., Honchel R., Goldblom S.E., McClaiw C.J. Tumor necrosis factor-mediated hypoalbuminemia in rabbits. J Nutr 1988, 119:1586-1590.
146. Zhang H., Voglis S., Kim C.H., Slutsky A.S. Effects of albumin and Ringer's lactate on production of lung cytokines and hydrogen peroxide after resuscitated hemorrhage and endotoxemia in rats. Crit Care Med 2003, 31:1515-1522.
147. Das U.N., Mohan I.K., Kumar K.V., Kumar G.S., Sekhar C.C. Beneficial effect of L-arginine in non-insulin dependent diabetes mellitus: A potential role for nitric oxide. Med Sci Res 1993, 21:669-670.